Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer

J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334. Epub 2015 Feb 9.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Crizotinib
  • Female
  • Gene Rearrangement*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Male
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*

Substances

  • Proto-Oncogene Proteins
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Protein-Tyrosine Kinases
  • ROS1 protein, human